Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Argen-X N.V. (Argenx). (5/19/15). "Press Release: Argen-X Awarded €1.5 million IWT Grant to Advance the Application of NHance Fc Modifications in Therapeutic Antibodies". Breda & Ghent.

Region Region Flanders (Flemish region)
  Country Belgium
Organisations Organisation Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Today Argenx SE (Euronext + Nasdaq: ARGX)
  Group Argenx (Argen-X) (Group)
  Organisation 2 IWT-Flanders (Institute for the Promotion of Innovation by Science and Technology in Flanders)
  Today VLAIO (Flanders Innovation & Entrepreneurship, Agentschap Innoveren & Ondernemen)
  Group Flanders (govt)
Products Product NHance™ technology
  Product 2 business development (state/region)
Index term Index term Argenx–Flanders (govt): grant, 201505 IWT grant €1.5m to advance NHance technology for modification of therapeutic antibodies
Persons Person Saunders, Michael (Elitech Group 200808 VP Marketing + BusDev)
  Person 2 Dible, David (Huntsworth 201506 Senior Director Life Sciences at Citigate Dewe Rogerson London)

arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). This grant will be used to advance and commercialize the application of the NHance® Fc modifications in therapeutic antibodies.

“We are very pleased to have received this support from IWT. As an organization, IWT has enabled the steady build of highly competitive Flemish biotechnology companies and we hope to continue this reputation with the advancement of our own novel, cutting edge research. NHance® is our proprietary approach to prolonging antibody circulation time. With the IWT grant, we aim to further confirm the benefit of antibodies equipped with NHance® by demonstrating enhanced tissue and tumor penetration with select antibody candidates in murine disease models,” commented Michael Saunders, Senior Director, Targets & Programs at arGEN-X. “In addition, efficient sweeping of the disease target by Fc modified antibodies can be further explored as NHance® has the game changing benefit of enhanced clearance of the target while the recycled antibody can be used for renewed target binding.”

arGEN-X’ technology suite consists of four complementary platforms. The proprietary SIMPLE Antibody™ discovery platform enables the targeting of complex or novel disease targets, and has been effective to-date in generating antibody leads with attributes beyond those attainable using current platforms. The Fc engineering technologies NHance®, ABDEG™ and POTELLIGENT®, have the potential to further enhance the intrinsic therapeutic functionalities of its antibody leads by prolonging product residence time in the human body, enhancing the clearance of disease targets or pathogenic antibodies and enhancing antibody cell killing through antibody-dependent cell-mediated cytotoxicity (ADCC), respectively. These technology platforms can be applied alone or in combination to yield differentiated therapeutic antibodies with multiple modes of action.

SIMPLE Antibody™, NHance® and ABDEG™ are trademarks of arGEN-X NV
POTELLIGENT® is a trademark of BioWa Inc.

For further information, please contact:

Joke Comijn
Corporate Communications Manager
+32 9 241 58 41
+32 477 77 29 44

arGEN-X BVBA (R&D Center)
Technologiepark 30
9052 Zwijnaarde
Belgium |

Mark Swallow
David Dible
Citigate Dewe Rogerson
+44 207 282 2949

Beth DelGiacco
Stern Investor Relations
+1 212 362 1200

About arGEN-X

arGEN-X combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

arGEN-X is listed on the Euronext Brussels exchange under the symbol ARGX.

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X’ actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Record changed: 2017-04-17


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Argenx (Argen-X) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top